Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...

Merck has stopped discussions to acquire cancer drug maker Revolution Medicines. The companies could not agree on a price for the deal. Tal...